/ /

Gary D. Novack, PhD
Novel therapies abound in pipeline
The importance of novel therapies for ocular disease is a given. However, as most novel therapies are financed by the private sector, it is fortunate that investors find ophthalmology a worthwhile investment.

Poll

View Results